Highlights from ACR Convergence 2023
View American College of Rheumatology educational opportunities here - https://rheumatology.org/events-programs
ACR Convergence 2023 Highlights: Efficacy and Safety of Intravenous Secukinumab for the Treatment of Active Psoriatic Arthritis: 16- and 52-Week Results from a Randomized, Double-Blind, Phase 3 Study
By
Highlights from ACR Convergence 2023
FEATURING
Alan Kivitz
By
Highlights from ACR Convergence 2023
FEATURING
Alan Kivitz
The above content is not sponsored by, nor part of, the American College of Rheumatology. ...
read more ↘
read more ↘
Comments 0
Login to view comments.
Click here to Login
